Beam Therapeutics (BEAM) News Today

Beam Therapeutics (NASDAQ:BEAM) Shares Down 6.6% Following Insider Selling

Scotiabank began coverage on shares of Beam Therapeutics in a report on Wednesday. They issued a "sector outperform" rating on the stock.

Squarepoint Ops LLC reduced its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 83.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,314 shares of the company's stock after selling 45,685 sh

Beam Therapeutics (NASDAQ:BEAM) Trading 6.8% Higher - Here's Why

Shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) have received an average rating of "Hold" from the thirteen ratings firms that are covering the stock, Marketbeat reports. Seven analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the

The Manufacturers Life Insurance Company increased its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 30.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 137,089 shares of the co

Dimensional Fund Advisors LP lifted its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 63.5% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 1,049,360 shares of the company's stock after acquiring an additional 407,499 shares

Bank of Montreal Can purchased a new stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the second quarter, according to its most recent filing with the SEC. The firm purchased 151,066 shares of the company's stock, valued at approximately $3,683,000. Bank of Montreal Can owne

Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) CEO John M. Evans sold 60,000 shares of the stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $24.60, for a total transaction of $1,476,000.00. Following the completion of the transaction, the chief executive officer now owns 938,659 shares in the company, valued at approximately $23,091,011.40. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

American Century Companies Inc. boosted its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 33.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 95,578 shares of the company's stock after buying an a

Scientech Research LLC raised its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 167.3% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 51,876 shares of the company's stock after acquiring an additional 32,

ARCH Venture Management LLC bought a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,443,039 shares of the company's stock, va

XTX Topco Ltd purchased a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 31,810 shares of the company's stock, valued at approxim

Rhumbline Advisers boosted its holdings in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 21.6% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 132,569 shares of the company's stock after ac

Shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) have been given a consensus recommendation of "Hold" by the thirteen research firms that are presently covering the stock, MarketBeat reports. Seven analysts have rated the stock with a hold rating and six have given a buy rating to

Stifel Nicolaus raised their price objective on Beam Therapeutics from $66.00 to $69.00 and gave the stock a "buy" rating in a report on Wednesday.

Beam Therapeutics (NASDAQ:BEAM) Trading Down 5.9%

Liontrust Investment Partners LLP acquired a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 80,000 shares of the company's stock, valued at approximately $

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities researchers at HC Wainwright issued their Q3 2024 earnings per share estimates for shares of Beam Therapeutics in a report released on Thursday, August 22nd. HC Wainwright analyst P. Trucchio expects that the company will earn ($0.98)

Baillie Gifford & Co. trimmed its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 17.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 623,640 shares of the company's stock after se

HC Wainwright restated a "buy" rating and set a $80.00 price target on shares of Beam Therapeutics in a research report on Thursday.

Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) has earned a consensus rating of "Hold" from the twelve ratings firms that are covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation and five have assigned a buy reco